(Approval lapsed) ​​CLAVULIN-125F amoxicillin and clavulanate potassium oral suspension 125mg/31.25mg per 5mL (Canada)​

Indicated for the treatment of the following infections when caused by amoxicillin and clavulanic acid sensitive, beta-lactamase producing organisms:

• skin and skin structure infections, including cases caused by beta-lactamase producing Staph. aureus, E. coli and Klebsiella sp. (only some strains may be sensitive).
• urinary tract infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis and Klebsiella sp.
• upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing H. influenzae and M. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and Staph. aureus.
• lower respiratory tract infections, especially cases caused by beta-lactamase producing H. influenzae and M. catarrhalis.

Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate.
The treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid should not require the addition of another antibiotic due to the amoxicillin content of the product.